litlas
Log inCreate account

Jacob Schachter

Active 1994–2025

94
Papers
28,795
Citations
61
h-index
88
i10-index

Citations

Citations per year for Jacob Schachter1993: 1 citations1995: 1 citations1996: 1 citations1997: 2 citations1998: 3 citations2000: 3 citations2001: 4 citations2002: 5 citations2003: 6 citations2004: 6 citations2005: 15 citations2006: 12 citations2007: 11 citations2008: 18 citations2009: 13 citations2010: 20 citations2011: 25 citations2012: 44 citations2013: 64 citations2014: 74 citations2015: 245 citations2016: 466 citations2017: 501 citations2018: 519 citations2019: 1,457 citations2020: 1,587 citations2021: 1,732 citations2022: 1,487 citations2023: 1,068 citations2024: 1,591 citations2025: 784 citations2026: 23 citations1994: no citations, so this year is not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,632 citing papers, 24.3% of this breakdownChina: 1,802 citing papers, 12.1% of this breakdownGermany: 878 citing papers, 5.9% of this breakdownItaly: 874 citing papers, 5.9% of this breakdownFrance: 783 citing papers, 5.2% of this breakdownUnited Kingdom: 743 citing papers, 5% of this breakdownAustralia: 668 citing papers, 4.5% of this breakdownNetherlands: 548 citing papers, 3.7% of this breakdownCanada: 475 citing papers, 3.2% of this breakdownSpain: 451 citing papers, 3% of this breakdownSwitzerland: 444 citing papers, 3% of this breakdownJapan: 330 citing papers, 2.2% of this breakdown
0%24.3%Other 22%

Institutions

Fields

  • Medicine64.1%
  • Biochemistry, Genetics and Molecular Biology24.6%
  • Immunology and Microbiology7.2%
  • Engineering0.9%
  • Nursing0.7%
  • Computer Science0.4%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers16%
  • CAR-T cell therapy research8.1%
  • Immunotherapy and Immune Responses7.5%
  • Melanoma and MAPK Pathways6%
  • Cutaneous Melanoma Detection and Management4.6%
  • Immune Cell Function and Interaction3%
  • Other54.8%

Coauthors

All papers

Open in search
  1. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    Authors: Erez N. Baruch, Ilan Youngster, Guy Ben‐Betzalel, Rona Ortenberg, Adi Lahat, Lior H. Katz, Katerina Adler, Daniela Dick‐Necula, Stephen Raskin, Naamah Bloch, Д. Л. Ротин, Liat Anafi, Camila Avivi, Jenny Melnichenko, Yael Steinberg‐Silman, Ronac Mamtani, Hagit Harati, Nethanel Asher, Ronnie Shapira‐Frommer, Tal Brosh‐Nissimov, Yael Eshet, Shira Ben-Simon, Ziv Oren, Md Abdul Wadud Khan, Moran Amit, Nadim J. Ajami, Iris Barshack, Jacob Schachter, Jennifer A. Wargo, Omry Koren, Gal Markel, Ben Boursi - Science 2020 cited by 1,682

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 cited by 5,847

  3. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    Authors: Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Maćkiewicz, Piotr Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V. Long - New England Journal of Medicine 2019 cited by 1,376

  4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Authors: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 cited by 1,153

  5. Identification of bacteria-derived HLA-bound peptides in melanoma

    Authors: Shelly Kalaora, Adi Nagler, Deborah Nejman, Michal Alon, Chaya Barbolin, Eilon Barnea, Steven L. C. Ketelaars, Kuoyuan Cheng, Kévin Vervier, Noam Shental, Yuval Bussi, Ron Rotkopf, Ronen Levy, Gil Benedek, Sophie Trabish, Tali Dadosh, Smadar Levin‐Zaidman, Leore T. Geller, Kun Wang, Polina Greenberg, Gal Yagel, Aviyah Peri, Garold Fuks, Neerupma Bhardwaj, Alexandre Reuben, Leandro C. Hermida, Sarah B. Johnson, Jessica Galloway-Peña, William C. Shropshire, Chantale Bernatchez, Cara Haymaker, Reetakshi Arora, Lior Roitman, Raya Eilam, Adina Weinberger, Maya Lotan‐Pompan, Michal Lotem, Arie Admon, Yishai Levin, Trevor D. Lawley, David J. Adams, Mitchell P. Levesque, Michal J. Besser, Jacob Schachter, Ofra Golani, Eran Segal, Naama Geva‐Zatorsky, Eytan Ruppin, Pia Kvistborg, Scott N. Peterson, Jennifer A. Wargo, Ravid Straussman, Yardena Samuels - Nature 2021 cited by 437

  6. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Authors: Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf - New England Journal of Medicine 2014 cited by 2,655

  7. Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    Authors: Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Richard Kefford, Jean‐Jacques Grob, Laurent Mortier, Caroline Robert, Jacob Schachter, Alessandro Testori, Jacek Mackiewicz, Philip Friedlander, Claus Garbe, Selma Ugurel, Frances A. Collichio, Wei Guo, Joelle Lufkin, Safi R. Bahcall, Vojo Vukovic, Axel Hauschild - Journal of Clinical Oncology 2013 cited by 386

  8. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

    Authors: Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood - New England Journal of Medicine 2017 cited by 1,475

  9. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Authors: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 cited by 1,239

  10. Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    Authors: Michal Harel, Rona Ortenberg, Siva Karthik Varanasi, Kailash Chandra Mangalhara, Mariya Mardamshina, Ettai Markovits, Erez N. Baruch, Victoria Tripple, May Arama-Chayoth, Eyal Greenberg, Anjana Shenoy, Rüveyda Ayasun, Naama Knafo, Shihao Xu, Liat Anafi, Gali Arad, Georgina D. Barnabas, Shira Ashkenazi, Michal J. Besser, Jacob Schachter, Marcus Bosenberg, Gerald S. Shadel, Iris Barshack, Susan M. Kaech, Gal Markel, Tamar Geiger - Cell 2019 cited by 340

  11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  12. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Authors: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 cited by 1,564

  13. Early and late hematologic toxicity following CD19 CAR-T cells

    Authors: Shalev Fried, Abraham Avigdor, Bella Bielorai, Amilia Meir, Michal J. Besser, Jacob Schachter, Avichai Shimoni, Arnon Nagler, Amos Toren, Elad Jacoby - Bone Marrow Transplantation 2019 cited by 401

  14. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

    Authors: Meir Rozenbaum, Amilia Meir, Yarden Aharony, Orit Itzhaki, Jacob Schachter, Ilan Bank, Elad Jacoby, Michal J. Besser - Frontiers in Immunology 2020 cited by 215

  15. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Authors: Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M. Kirkwood, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V. Long, Dirk Schadendorf - New England Journal of Medicine 2020 cited by 407

  16. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

    Authors: Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, Olga Vornicova, Jacob Schachter, Abhishek Joshi, Nicolás Meyer, Florent Grange, Josep M. Piulats, Jessica R. Bauman, Pingye Zhang, Burak Gümüşçü, Ramona F. Swaby, Brett Hughes - Journal of Clinical Oncology 2020 cited by 289

  17. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Matteo S. Carlino, Catriona M. McNeil, Antoni Ribas, Jean‐Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil Daud, Omid Hamid, James Larkin, James R. Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long - Journal of Clinical Oncology 2023 cited by 113

  18. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    Authors: Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz‐Merino, André van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long - Journal of Clinical Oncology 2022 cited by 162

  19. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    Authors: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J. Diede, Elizabeth Croydon, Antoni Ribas, Paolo A. Ascierto - Journal for ImmunoTherapy of Cancer 2020 cited by 173

  20. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Authors: Georgina V. Long, Axel Hauschild, Mario Santinami, John M. Kirkwood, Victoria Atkinson, Mario Mandalà, Barbara Merelli, Vanna Chiarion‐Sileni, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, James Larkin, Monique Tan, Sachin Bajirao Adnaik, Paul Burgess, Tarveen Jandoo, Reinhard Dummer - New England Journal of Medicine 2024 cited by 125

  21. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

    Authors: Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia V. Zhukova, Jacob Schachter, Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Grant A. McArthur, Ralf Gutzmer - The Lancet Oncology 2022 cited by 104

  22. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Authors: Brett Hughes, E. Munoz-Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, B. Gumuscu, Ramona F. Swaby, Jean‐Jacques Grob - Annals of Oncology 2021 cited by 200

  23. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    Authors: Michal J. Besser, Ronnie Shapira‐Frommer, Orit Itzhaki, Avraham J. Treves, Douglas Zippel, Daphna Levy, Adva Kubi, Noa Shoshani, Dragoslav Zikich, Yaara Ohayon, Daniel Ohayon, Bruria Shalmon, Gal Markel, Ronit Yerushalmi, Sara Apter, Alon Ben‐Nun, Eytan Ben‐Ami, Avichai Shimoni, Arnon Nagler, Jacob Schachter - Clinical Cancer Research 2013 cited by 383

  24. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

    Authors: Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana Dronca, Richard W. Joseph, C. Boutros, Le Min, Georgina V. Long, Jacob Schachter, Igor Puzanov, Reinhard Dummer, Jianxin Lin, Nageatte Ibrahim, Scott J. Diede, Matteo S. Carlino, Anthony M. Joshua - European Journal of Cancer 2020 cited by 100